Dr. Reddy’s Laboratories has launched Hervycta (trastuzumab), a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer). Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials. Commenting on the launch, MV Ramana, CEO-Branded Markets (India and Emerging Markets),…
FDA Approves First Generic Version Of Suboxone
Dr. Reddy’s Laboratories announced today that it has received final approval from the FDA and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The product is being launched…
Dr. Reddy’s Launches Levocetirizine Dihydrochloride Tablets In U.S. Market
The FDA has approved Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing. “This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” says Milan Kalawadia, Vice President and Head,…